title: [The treatment of bacterial infections of the lower respiratory tract in childhood. An open comparative study of sulbactam/ampicillin vs. ceftazidime].
abstract: Sixty children suffering from lower respiratory tract infections have been included into this study, respectively 30 (18 M + 12 F) in the sulbactam/ampicillin (S/A) group and 30 (20 M + 10 F) in the ceftazidime (CFT) group. Average age was 42.9 months +/- 34.4 in S/A group (range 6-120) and 48.7 +/- 42.1 (range 6-144) in CFT group. Both groups were similar as to sex, age, type and duration of the infection. Posology was 150 mg/kg/die for S/A and 50 mg/kg/die for CFT. The duration of treatment was 7.2 days +/- 2.2 (range 5-12) for S/A group and 6.4 days +/- 1.6 (range 5-12) for CFT group. At the end of the therapy clinical recovery has been obtained in all cases. A rapid defervescence and remission of symptoms at an identical rate has been recorded in both treatment groups. General and local tolerability was excellent in both treatment groups.
authors: Divisione di Pneumologia, U.S.L. Bari II, Presidio Ospedaliero Pediatrico Giovanni XXIII, Bari.
authors: L
authors: L
authors: Longo
authors: A
authors: A
authors: Pugliese
authors: R
authors: R
authors: Schiavone
authors: L
authors: L
authors: Fumarola
authors: S
authors: S
authors: Federici
authors: M G
authors: MG
authors: De Lucia
authors: M P
authors: MP
authors: Canale
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000667:Ampicillin / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D012074:Remission Induction; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013407:Sulbactam / Q000627:therapeutic use*
chemical_list: D000667:Ampicillin; D002442:Ceftazidime; D013407:Sulbactam
vernacular_title: Trattamento delle infezioni batteriche delle basse vie respiratorie in età pediatrica. Studio aperto comparativo sulbactam/ampicillin vs ceftazidime.